ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC (Nasdaq: ORIC) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company completed dose exploration for ORIC-944 Phase 1b and selected provisional RP2Ds (400/600 mg with darolutamide; 600/800/1,200 mg with apalutamide). In 20 mCRPC patients, ORIC reported PSA50 55% (PSA90 20%) and ctDNA reductions: >50% in 76% and ctDNA clearance 59%. Safety profile compatible with long-term dosing; one Grade 3 TRAE, no Grade 4/5 attributed. Enozertinib INN approved; multiple Phase 1b cohorts enrolling. Corporate: CTO appointment and $413.0M cash/investments expected to fund operations into 2H 2028.
ORIC (Nasdaq: ORIC) reported Phase 1b dose exploration results for once-daily ORIC-944 combined with apalutamide or darolutamide in mCRPC on Nov 13, 2025. Key efficacy signals: PSA50 55% (11/20), PSA90 20% (4/20), rapid/deep ctDNA reductions in 76% (13/17) and ctDNA clearance in 59% (10/17). Safety was compatible with long-term dosing: most TRAEs Grade 1–2, one Grade 3 TRAE, no Grade 4/5 attributed to study drugs as of Sep 22, 2025. Provisional RP2Ds were selected and dose optimization data are expected in 1Q 2026, with a planned global Phase 3 start in 1H 2026.
ORIC Pharmaceuticals (Nasdaq:ORIC) disclosed inducement equity awards granted on November 3, 2025 to a new non-executive employee who started in October 2025. The company granted 18,400 non-qualified stock options and 3,000 restricted stock units (RSUs) under the 2022 Inducement Equity Incentive Plan, subject to continued service through vesting dates.
The stock options have an exercise price equal to ORIC's closing common-stock price on the grant date. Options vest 25% after one year, then 1/36th monthly thereafter; RSUs vest one-third on each of the first three anniversaries. Grants were approved by the Compensation Committee and made pursuant to Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) announced a peer-reviewed publication in Cancer Research describing the discovery and preclinical development of enozertinib, an oral, irreversible EGFR inhibitor designed for EGFR exon 20 and atypical mutations. The paper reports enozertinib’s exquisite kinome selectivity, strong potency, and brain penetration, with anti-tumor activity in intracranial lung cancer models. The publication includes a patient vignette reporting a sustained systemic and CNS complete response in an NSCLC patient with an EGFR exon 20 insertion. ORIC said it will present multiple clinical datasets in December 2025 (ESMO Asia 2025) and additional 1L combination data in mid-2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced management will participate in three investor conferences in November 2025: a fireside chat at Guggenheim’s 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 at 1:30 p.m. ET, one-on-one meetings at Stifel 2025 Healthcare Conference on Nov 12, 2025, and a fireside chat at Jefferies London Healthcare Conference on Nov 19, 2025 at 2:30 p.m. GMT. Management will also hold one-on-one meetings at the Guggenheim and Jefferies events.
Webcasts of the fireside chats will be available via the company’s investor website and replays will remain available for 90 days following each event.
ORIC Pharmaceuticals (Nasdaq: ORIC) presented preclinical data on ORIC-944, an allosteric PRC2 inhibitor targeting EED, at the 2025 EORTC-NCI-AACR conference on October 27, 2025. Key findings show ORIC-944 combined with androgen receptor (AR) inhibitors delayed relapse and improved survival in castration-sensitive prostate cancer preclinical models by restricting cellular plasticity and lineage adaptation. In KRAS G12C models, ORIC-944 plus the KRAS inhibitor adagrasib regressed 100% of tumors in NSCLC xenografts, prevented tumor relapse and extended progression-free survival. Transcriptional and chromatin changes consistent with PRC2 inhibition were reported across tumor types.
All results reported are preclinical and described as supporting ORIC-944's potential as a best-in-class PRC2 inhibitor.
ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has granted equity-based inducement awards to a new non-executive employee who joined in August 2025. The grants include 292,500 non-qualified stock options and 79,000 restricted stock units.
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in five major investor conferences in September 2025. The company will engage in fireside chats and one-on-one meetings at the Citi Biopharma Back to School Summit, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.
Webcasts of the fireside chat discussions will be accessible through ORIC's investor relations website, with replays available for 90 days after each event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has appointed Kevin Brodbeck, PhD as its first Chief Technical Officer (CTO), strengthening its leadership team ahead of potential Phase 3 trials in 2026. Dr. Brodbeck brings over 25 years of experience in technical operations, quality assurance, and CMC activities.
The strategic appointment comes as ORIC prepares for late-stage development of two key programs: ORIC-944 and enozertinib (ORIC-114). Dr. Brodbeck's previous roles include Chief Technical and Development Operations Officer at Deciphera Pharmaceuticals and SVP of Technical Operations at Nektar Therapeutics, where he led various development programs and managed global CMC operations.
ORIC Pharmaceuticals (Nasdaq: ORIC) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company secured $244 million in financing, including a $125 million private placement and $119 million from ATM issuances, extending its cash runway into 2H 2028.
Key highlights include promising Phase 1b trial results for ORIC-944 in prostate cancer treatment, showing a 59% PSA50 response rate and 24% PSA90 response rate. The company is advancing both ORIC-944 and ORIC-114 (enozertinib) towards potential Phase 3 trials in 2026. As part of a strategic restructuring, ORIC is reducing its discovery research investment, resulting in a 20% workforce reduction.